Please login to the form below

Not currently logged in
Email:
Password:

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

AstraZeneca

Grünenthal has acquired the rights to AstraZeneca’s migraine drug Zomig for up to $302m as the UK pharma firm continues to sharpen its strategic focus.

AstraZeneca has sold a raft of older or non-core products over the past two years, including a $230m deal with Grünenthal for gout drug Zurampic.

Mark Mallon, EVP, global product and portfolio strategy at AstraZeneca, said: “Grünenthal is an established partner with expertise in the treatment of pain. It is well placed to ensure patients continue to benefit from Zomig, and to extend the commercial potential of the medicine through its dedicated salesforce.”

The companies’ latest agreement covers global rights outside Japan to Zomig (zolmitriptan), a treatment for migraines and cluster headaches for which Grünenthal will pay $200m up front and up to $102m in milestones.

Gabriel Baertschi, CEO of Grünenthal, said: “The acquisition of the well-established Zomig products complements our existing pain portfolio. Migraine has been one of the very few main pain indications we haven’t yet been able to offer a solution for.

“This is an important step to reach our ambition to become a €2bn company by 2022. It will also support our efforts to bring four to five innovative products to market in the same timeframe.”

It’s thought that more than 75 million people around the world suffering from migraine attacks, which can lead to nausea and vomiting.

AZ has been busy focusing its efforts on its core therapeutic categories - namely oncology, inflammation and autoimmunity and cardiovascular/metabolic diseases - as it tries to meet chief executive Pascal Soriot's objective of boosting sales to $45bn by 2023.

This work has seen it agree deals with TerSera Therapeutics ($320m for Zoladex), ProStakan ($70m for Moventig), Aspen ($770m for seven anaesthetics drugs) and, most recently, Recordati ($300m for two blood pressure brands).

Article by
Dominic Tyer

7th June 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....